Key result
Growth hormone replacement for 6 months significantly reduced mean carotid intima-media thickness and improved cardiovascular risk factors in adults with severe GH deficiency.
Why the study?
Does growth hormone replacement therapy improve cardiovascular risk factors and carotid intima-media thickness in adult patients with severe GH deficiency?
RCT (n=34)
randomized, cross-over
Does growth hormone replacement therapy improve cardiovascular risk factors and carotid intima-media thickness in adult patients with severe GH deficiency?
Six months of growth hormone replacement therapy improves cardiovascular risk factors and reduces carotid intima-media thickness in adults with severe GH deficiency.
Answers are grounded in this paper and cite their sources.
Supports GH replacement in severe adult GH deficiency; reinforces cardiovascular benefits with RCT evidence.
To explore early effects of GH treatment or deprivation on cardiovascular risk factors and carotid intima-media thickness (IMT), we designed this randomized, cross-over study in 34 adult patients with severe GH deficiency. At study entry, the patients were randomized into two groups (A and B); group A (n = 17) received appropriate replacement therapy including GH at standard doses for 6 months and then were withdrawn from GH for the subsequent 6 months; group B (n = 17) received appropriate replacement therapy excluding GH for 6 months with the addition of GH in the subsequent 6 months. After the first 6 months, we observed a significant increase in IGF-I levels and of high-density lipoprotein (HDL)-cholesterol together with a significant decrease in diastolic blood pressure, the total/HDL-cholesterol ratio, and C-reactive protein in the patients in group A, whereas vascular parameters did not significantly change. In the patients in group B, none of the parameters studied significantly changed. After 6 months of GH withdrawal in the patients in group A, a significant decrease in IGF-I levels, a significant increase in the total/HDL-cholesterol ratio and C-reactive protein, and a trend toward an impairment of carotid IMT and peak velocities were observed. In the patients in group B, the addition of GH to the standard replacement induced a significant increase in IGF-I levels together with a decrease in systolic and diastolic blood pressure, total cholesterol and total/HDL-cholesterol ratio, and C-reactive protein, and an increase in HDL-cholesterol levels with a trend toward an improvement of vascular parameters. At the end of the study, mean IMT was significantly lower than at baseline both in group A (from 0.88 +/- 0.28 to 0.85 +/- 0.27 mm, P = 0.0003) and in group B (from 0.83 +/- 0.21 to 0.80 +/- 0.20 mm, P = 0.003). In conclusion, 6 months of GH replacement has beneficial effects whereas 6 months of GH deprivation has detrimental effects on cardiovascular risk factors and atherosclerosis. These findings support the indication for GH replacement in severe GH deficiency adult patients.
No takes yet. Share an insight, caveat, or question.
Colao et al. (2005) conducted an RCT in severe GH deficiency (n=34). Growth Hormone (GH) vs. GH deprivation was evaluated on carotid intima-media thickness (IMT) (p=0.0003). Growth hormone replacement for 6 months significantly reduced mean carotid intima-media thickness and improved cardiovascular risk factors in adults with severe GH deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: